XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
BASIS OF PRESENTATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Net loss     $ (4,790,597) $ (3,010,684)            
Accumulated deficit $ (71,038,463)   (71,038,463)       $ (66,232,813)      
Stockholders' equity 44,195,740 $ 3,443,833 44,195,740 3,443,833 $ 43,669,058 $ 44,007,783 $ 39,284,295 $ 5,130,056 $ 4,910,249 $ 4,379,463
Revenue 12,823,797 $ 12,016,098 37,537,003 $ 38,296,402            
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                    
Net loss     (4,790,597)              
Net cash used in operations     16,587,726              
Working capital 23,901,453   23,901,453              
Accumulated deficit (71,038,463)   (71,038,463)              
Stockholders' equity $ 44,195,740   44,195,740              
Revenue     $ 37,537,003